Pharmaceuticals
Samsung Biologics signs development agreement with Panolos for solid tumor treatment
INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung Biologics will provide a full scope of its developm...
2020-09-17 08:43
2624
Transcenta Successfully Scaled up the Continuous Perfusion Process and Completed GMP Manufacturing of a Novel Bispecific Antibody for Cancer Immunotherapy
SUZHOU, China and HANGZHOU, China, Sept. 15, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company, today announced success in scaling up the continuous perfusion process to 200L and completion of GMP production of a bispecific antibody for a Phase 1 clinical study. "This is an impo...
2020-09-15 23:00
1705
NaviFUS Launches Neuronavigation-guided Clinical Trial to Open the Blood-Brain-Barrier for Combination FUS-Bevacizumab Therapy in rGBM Patients
TAIPEI, Sept. 11, 2020 /PRNewswire/ -- Genovate Biotech (TPEX:4130) subsidiary andTaiwan-based focused ultrasound (FUS) manufacturer NaviFUS Corporation is pleased to announce the start of its clinical trial (NCT04446416) for the combination of FUS plus bevacizumab therapy. Researchers at Linkou ...
2020-09-11 20:55
3950
Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Clene Nanomedicine, Inc.
NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Tottenham Acquisition I Limited (Nasdaq: TOTA, TOTAU, TOTAW, TOTAR) ("Tottenham"), a publicly traded special purpose acquisition company, announced today that its subsidiary, Chelsea Worldwide Inc., has filed with the U.S. Securities and Exchange Commissio...
2020-09-10 20:56
21651
NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement
TAIZHOU, China, Sept. 9, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Ad...
2020-09-09 21:00
9488
I-Mab Announces Upcoming Participation at September Conferences
SHANGHAI and GAITHERSBURG, Md., Sept. 8, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Septem...
2020-09-08 20:00
9343
Executive from Yuyu Pharma Receives Presidential Commendation for Gender Equality Employment
SEOUL, South Korea, Sept. 4, 2020 /PRNewswire/ -- Eugene Baik, Head of Production at Yuyu Pharma (CEORobert Wonsang Yu, KRX 000220), received the Presidential Commendation for contributions in leading the realization of gender equality employment. The award was given at the 2020 Gender Equality ...
2020-09-04 21:00
3797
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
SHANGHAI and GAITHERSBURG, Md., Sept. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it has entered into definitive subscription agreeme...
2020-09-04 19:01
11299
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
NORTH CHICAGO, Illinois and SHANGHAI, China, Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (Nasdaq: IMAB) announced today that AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an inn...
2020-09-04 19:00
10432
111, Inc. Partners with Baiyunshan Pharmaceutical Sales in Digital Medicine Innovation
SHANGHAI, Sept. 4, 2020 /PRNewswire/ -- On August 25, 111, Inc. ("111" or the "Company") (Nasdaq: YI), a company dedicated to digitally connecting patients with drugs and healthcare services inChina, and Guangzhou Baiyunshan Pharmaceutical Sales Co., Ltd. ("Baiyunshan Pharmaceutical Sales"), an ...
2020-09-04 18:22
10041
Alphamab Oncology announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KN046 for the treatment of thymic epithelial tumor
SUZHOU, China, Sept. 3, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to KN046, a recombinant humanized PD-L1/CTLA-4 bispecific antibody developed by Jiangsu Alphamab Biopharmaceuti...
2020-09-03 23:46
2191
PharmAbcine signs a CMO contract with Binex so Binex can produce olinvacimab at its new 5,000L production line
DAEJEON, South Korea, Sept. 2, 2020 /PRNewswire/ -- PharmAbcine (KRX: 208340ks), a biotech company focusing on the development of antibody therapeutics, announcedon August 31 that it had signed a contract manufacturing organization(CMO) agreement with Binex, a leading biologics CDMO(Contract Dev...
2020-09-02 21:00
1965
Clene Nanomedicine, Inc. to go Public through Merger with Tottenham Acquisition I Limited
* Clene is a clinical-stage biopharmaceutical company developing the first potential therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neur...
2020-09-02 20:00
18848
Innovent Announces First Subject Dosed in the Phase 1 Clinical Trial of Anti-IL-23 Monoclonal Antibody
SAN FRANCISCO, and SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2020-09-01 08:00
2405
Transcenta Announces First Patient Dosed in Phase I China Trial of Claudin18.2 Targeting Monoclonal Antibody TST001
SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today that the first subject has been dosed successful...
2020-08-31 23:00
2032
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update
Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated drug profile in safety and pharmacokinetics in cancer patients Joined the global effort against COVID-19 with plonmarlimab (TJM2) study which represents the first double-blind, placebo-controlled st...
2020-08-31 19:00
14218
Yiling Pharmaceutical Reports 52.75% YOY Growth in R&D Investment, Boosting the Company's High Quality Development
SHIJIAZHUANG, China, Aug. 28, 2020 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) on Thursday published its semiannual report of 2020. In the reporting period, the Company registered business revenues of4.487 billion RMB, a year-on-year growth of 50.35%; net profits earned by shareholders of t...
2020-08-28 18:27
11637
HJB and Ansun Biopharma Enter Strategic Agreement on Biologics CMC Development and Manufacturing Partnership
HANGZHOU, China, Aug. 27, 2020 /PRNewswire/ -- HJB, a biologics Contract Development and Manufacturing Organization (CDMO) committed to quality, reliability and speed for each and every CMC package delivered to its partners, announces it enters into a strategic partnership for CMC development and ...
2020-08-27 23:00
2321
Fosun Pharma Announces 2020 Interim Results
SHANGHAI, Aug. 26, 2020 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group inChina, announced its interim results for the year 2020 ("the Reporting Period"). During the Reporting Period： * The revenue ac...
2020-08-26 22:03
14190
RoboPharma Acquired by Capsa Healthcare to Broaden Reach Into New Pharmacy Automation Markets
WAALWIJK, Netherlands, Aug. 26, 2020 /PRNewswire/ -- RoboPharma announced today the company has been acquired by Capsa Healthcare, a worldwide innovator in healthcare delivery solutions for hospitals, senior care settings, and retail pharmacy providers. Becoming an integral segment within Capsa H...
2020-08-26 08:12
2491
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116